NCT03202940 2025-09-25
A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC
Massachusetts General Hospital
Phase 1/2 Active not recruiting
Clinical Trials
5 trialsNCT04214418 2024-12-18
MEKiAUTO
Columbia University
Phase 1/2 Terminated
NCT03101254 2024-07-17
LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT01959633 2022-02-24
VEMUPLINT
Fondazione Melanoma Onlus
Phase 1/2 Completed
NCT03566485 2021-08-11
Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 1/2 Terminated